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For decades, the standard adjuvant endocrine therapy for post-
menopausal women with estrogen receptor (ER)– and/or proges-
terone receptor (PgR)–positive breast cancer was 5 years of the 
selective ER modulator tamoxifen, which improved disease-free 
survival and reduced the annual breast cancer death rate by 31% 
(1). Recent reports from the Breast International Group (BIG) 
1-98 trial have shown that adjuvant therapy with the aromatase 
inhibitor letrozole given as a single agent for 5 years improves 
disease-free and overall survival compared with 5 years of tamoxifen 
in this population (2–5). However, there may be groups of patients, 
for example, those at lower risk for recurrence, for whom tamoxifen 
or a sequence of the two agents represents a reasonable choice 
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 Background Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. 
Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 
polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of 
CYP2D6 polymorphisms.
 Methods We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone 
receptor–positive breast cancer who enrolled in the randomized, phase III double-blind Breast International 
Group (BIG) 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment. 
Extracted DNA was used for genotyping nine CYP2D6 single-nucleotide polymorphisms using polymerase chain 
reaction–based methods. Genotype combinations were used to categorize CYP2D6 metabolism phenotypes as 
poor, intermediate, and extensive metabolizers (PM, IM, and EM, respectively; n = 4393 patients). Associations 
of CYP2D6 metabolism phenotypes with breast cancer-free interval (referred to as recurrence) and treatment-
induced hot flushes according to randomized endocrine treatment and previous chemotherapy were assessed. 
Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). 
All statistical tests were two-sided.
 Results No association between CYP2D6 metabolism phenotypes and breast cancer-free interval was observed among 
patients who received tamoxifen monotherapy without previous chemotherapy (P = .35). PM or IM phenotype 
had a non-statistically significantly reduced risk of breast cancer recurrence compared with EM phenotype (PM 
or IM vs EM, HR of recurrence = 0.86, 95% CI = 0.60 to 1.24). CYP2D6 metabolism phenotype was associated 
with tamoxifen-induced hot flushes (P = .020). Both PM and IM phenotypes had an increased risk of tamoxifen-
induced hot flushes compared with EM phenotype (PM vs EM, HR of hot flushes = 1.24, 95% CI = 0.96 to 1.59; 
IM vs EM, HR of hot flushes = 1.23, 95% CI = 1.05 to 1.43).
 Conclusions CYP2D6 phenotypes of reduced enzyme activity were not associated with worse disease control but were 
associated with increased hot flushes, contrary to the hypothesis. The results of this study do not support using 
the presence or absence of hot flushes or the pharmacogenetic testing of CYP2D6 to determine whether to treat 
postmenopausal breast cancer patients with tamoxifen.
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(4,6), and others for whom the availability and/or side effects 
of aromatase inhibitor therapy make tamoxifen the preferable 
treatment. Thus, there is considerable interest in defining the 
population of patients who have the greatest chance of benefiting 
from tamoxifen.
Early clinical investigation of the pharamacogenetics of tamox-
ifen metabolism showed promise that a pharmacogenetic testing of 
Cytochrome P450 2D6 (CYP2D6) phenotype to identify patients 
with reduced tamoxifen metabolism could predict poorer respon-
siveness to tamoxifen in terms of disease recurrence (7). A mod-
eling study further suggested that patients with a phenotype of 
extensive tamoxifen metabolism may receive equal benefit from 
tamoxifen as from an aromatase inhibitor (8). However, in more 
than one dozen subsequent clinical investigations, the results are 
conflicting (9,10), and the evidence base is inconclusive. With 
CYP2D6 pharmacogenetic testing now clinically available, there is 
uncertainty among patients, health-care providers, health author-
ities, and insurers about its utility for patient care.
The underlying hypothesis is that CYP2D6 polymorphisms 
leading to reduced CYP2D6 enzyme activity result in lower plasma 
concentrations of endoxifen, which adversely affects tamoxifen 
efficacy. Tamoxifen has relatively weak affinity for ER and 
undergoes extensive primary and secondary metabolism, principally 
by the highly polymorphic enzyme of the CYP2D6 gene (11,12), to 
form clinically active metabolites 4-hydroxytamoxifen and endoxifen 
(4-hydroxy-N-desmethyltamoxifen), which have 30- to 100-fold 
greater affinity for ER compared with tamoxifen (13,14). Endoxifen 
is believed to be the most clinically active metabolite (15–17). 
Patients’ plasma concentrations of tamoxifen, endoxifen, and 
4-hydroxytamoxifen vary widely, but studies have shown that 
CYP2D6 reduced metabolism phenotypes to be associated with 
lower endoxifen levels (16,18,19). Lower endoxifen levels are also 
hypothesized to result in fewer or less severe tamoxifen-induced 
hot flushes (7,20,21).
We investigated the clinical relevance of CYP2D6 metabolism 
phenotype in the BIG 1-98 trial. We hypothesized that CYP2D6 
phenotypes of reduced CYP2D6 enzyme activity would be associ-
ated with worse disease control among tamoxifen-treated, postmen-
opausal hormone receptor–positive breast cancer patients and 
would be associated with reduced onset of tamoxifen-induced hot 
flushes. Unlike previous studies that mostly focused on patients who 
received tamoxifen without previous chemotherapy, our investiga-
tions separated patients according to previous chemotherapy use.
Methods
Patients
The BIG 1-98 study is an international, randomized, phase III 
double-blind trial comparing 5 years of monotherapy with tamoxifen 
(20 mg daily) or with letrozole (2.5 mg daily) or a sequential 
therapy of 2 years of one of these agents (same daily dose) followed 
by 3 years of the other (2–5) among postmenopausal women with 
ER- and/or PgR-positive, operable invasive breast cancer 
(Supplementary Figure 1, available online). A total of 8010 women 
were enrolled between March 1998 and May 2003. Centers partic-
ipated in one of two randomization options (two-arm and four-arm): 
from March 1998 through March 2000, women were randomized 
to receive only letrozole or only tamoxifen for 5 years; and from 
April 1999 through May 2003, women were randomly assigned to 
one of four study treatments.
All participants provided written informed consent. Ethics 
committees and relevant health authorities approved the protocol. 
Trial participants were followed clinically at baseline, every 6 months 
for the first 5 years during blinded study drug dispensing, and 
yearly thereafter. Specific adverse events were listed on the case 
report forms and graded according to the Common Toxicity 
Criteria (CTC) v2.0 at study visits, including hot flushes (CTC 
grade 1 = mild or no more than one per day; grade 2 = moderate 
and greater than one per day) and night sweating (CTC grade 
1 = mild and occasional; grade 2 = frequent or drenching).
Tissue Collection, DNA Extraction, and CYP2D6 
Genotyping
Retrospective tissue collection was carried out by the International 
Breast Cancer Study Group (IBCSG) and the Danish Breast 
CONTEXT AND CAVEATS
Prior knowledge
Women with hormone receptor–positive breast cancer are treated 
with tamoxifen. Because cytochrome P450 2D6 (CYP2D6) metabo-
lizes tamoxifen to clinically active metabolites, it is suggested that 
pharmacogenetic testing of CYP2D6 polymorphisms to identify 
patients with reduced tamoxifen metabolism phenotypes may 
predict poorer responsiveness to tamoxifen.
Study design
DNA from tumor tissues of postmenopausal breast cancer patients 
who participated in the Breast International Group (BIG) 1-98 trial 
and received adjuvant tamoxifen and/or letrozole treatment was 
used for CYP2D6 genotyping. CYP2D6 metabolism phenotypes 
were classified as poor, intermediate, and extensive metabolizers 
(PM, IM, and EM, respectively), and associations with breast 
cancer-free interval and treatment-induced hot flushes were 
assessed according to randomly assigned endocrine treatment and 
previous chemotherapy.
Contribution
CYP2D6 metabolism phenotypes showed no association with 
breast cancer-free interval among patients who received tamoxifen 
without previous chemotherapy. The PM and IM phenotypes 
showed an increased rate of tamoxifen-induced hot flushes com-
pared with EM phenotype, which was contrary to the hypothesis.
Implications
Phenotypes of reduced CYP2D6 enzyme activity were not associ-
ated with worse disease control or reduced tamoxifen-induced hot 
flushes. Results do not support the pharmacogenetic testing of 
CYP2D6 to predict the efficacy of tamoxifen in postmenopausal 
hormone receptor–positive breast cancer patients.
Limitations
BIG 1-98 trial did not collect data on concomitant medications. 
Therefore, this study could not address whether patients should 
avoid concomitant medication of tamoxifen and CYP2D6 inhibitors. 
Some misclassification of metabolism phenotypes may have 
occurred.
From the Editor
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Cancer Collaborative Group between 1998 and 2010 in accor-
dance with institutional guidelines and national laws. BIG 1-98 
Collaborative Group members who submitted tumor blocks are 
listed in Supplementary Appendix (available online). Funding 
was provided to participating institutions by the BIG 1-98 
trial’s pharmaceutical partner, Novartis, to partially cover associ-
ated costs. The IBCSG Biological Protocols Working Group 
approved this project. All material processing and genotyping were 
done without the knowledge of patients’ treatment assignments 
or outcomes.
Formalin-fixed paraffin-embedded primary breast cancer tissue 
blocks for 5786 patients were assessed for adequacy of invasive 
tumor material to extract nucleic acids. In 5166 tumor blocks from 
patients, an area that was representative of the invasive tumor 
component was identified, and one or two 1-mm cores were 
punched in this area. DNA was isolated for 4861 of 8010 trial 
patients (Figure 1). Genomic DNA was extracted using the 
QIAamp DNA formalin-fixed paraffin-embedded tissue kit 
(Qiagen, Valencia, CA) according to manufacturer’s instructions. 
DNA was eluted with 60 µL of sterile distilled water, quantified, 
and quality controlled according to the 260/280 nm ratio using the 
Infinite M 200 NanoQuant (Tecan, Mannedorf, Switzerland) and 
aliquoted at a concentration of 10 ng/µL.
The DNA samples from patients were genotyped for nine 
CYP2D6 single-nucleotide polymorphisms (SNPs) that were 
selected to maximize CYP2D6 phenotype prediction by capturing 
approximately 99% of CYP2D6 genotypes: the most common null 
allele CYP2D6*4 (1846G>A [rs3892097]); three SNPs that 
together determine CYP2D6*2, CYP2D6*10, and CYP2D6*41 alleles 
and rule out the possibility of CYP2D6*5 allele (ie, 4180G>C 
[rs1135840], 100C>T [rs1065852], and 2988G>A [rs28371725]); 
and five SNPs for determining four less common alleles CYP2D6*3, 
CYP2D6*6, CYP2D6*7, and CYP2D6*17 (ie, 2549delA 
[rs35742686], 1707delT [rs5030655], 2935A>C [rs5030867], 
1023C>T [rs28371706], and 2850C>T [rs16947]) (22) 
(Supplementary Table 1, available online). Samples were geno-
typed in a Clinical Laboratory Improvement Amendments (CLIA)– 
accredited laboratory using polymerase chain reaction (PCR)–based 
methods: the GenomeLab SNPstream Genotyping System 
(Beckman Coulter, Brea, CA); and the 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Foster City, CA). For SNPstream 
genotyping, we used three primers for each SNP; two primers for 
the initial PCR reaction and one for the single-base extension 
reaction were designed and grouped into 48-plexed panels. Using 
2–10 ng of genomic DNA, a 48-plex PCR was carried out in 
384-well plate to amplify an approximately 100 bp region flanking 
each SNP. The reaction was treated with ExoSAP reagent to remove 
any leftover PCR primers and deoxynucleotide triphosphates 
(dNTPs). The 48-plex extension primer pool was then added to the 
same PCR plate. A single-base extension reaction was performed to 
incorporate a differentially labeled fluorescent dNTP to the SNP 
position. The extension reaction was transferred to a Tag Array and 
spatially resolved to distinguish the 48 SNPs. All reagents were 
preformulated and included in the GenomeLab SNPware Reagent 
kit (Beckman Coulter Inc, Fullerton, CA). The GenomeLab 
SNPstream Genotyping System Software Suite v2.3 (Beckman 
Coulter Inc) was used for array imaging and genotype calling. For 
the CYP2D6*4 (1846G>A [rs3892097]) and CYP2D6*41 (2988G>A 
[rs28371725]) SNPs, commercially available pre-designed TaqMan 
assays (Applied Biosystems) were used and run on the 7900HT 
Fast Real-Time PCR System. The optimization was done using 
Applied Biosystems’ TaqMan probes, in conjunction with the 
KlearKall Mastermix (KBioscience, Beverly, MA). The PCR con-
ditions were as follows: 95°C for 10 minutes followed by 40 cycles 
of 95°C for 15 seconds and 60°C for 1 minute and then hold at 
4°C. For CYP2D6*41, the cycle number was increased to 45 cycles 
and for CYP2D6*4, the cycle number was increased to 60 cycles.
As described previously (23), we categorized patients according 
to predicted CYP2D6 metabolism phenotypes based on genotype 
combinations: poor metabolizer (PM) phenotypes were homozy-
gous or compound heterozygous for CYP2D6*3, CYP2D6*4, 
CYP2D6*6, or CYP2D6*7 alleles (PM alleles); intermediate metab-
olizer (IM) phenotypes carried either homozygous CYP2D6*41 
alleles (IM alleles) or a CYP2D6*41 allele in combination with a 
PM allele (ie, IM/IM or IM/PM alleles, respectively), or were 
heterozygous carriers of one PM or IM allele with an extensive 
metabolizer (EM) allele (ie, heterozygous for extensive metabo-
lizer allele [hetEM]); EM phenotypes were characterized by the 
absence of PM and IM alleles.
Statistical Analysis
Breast cancer-free interval (BCFI) was analyzed among patients 
who were randomly assigned to 5 years of tamoxifen or letrozole 
monotherapy and was defined from random assignment to the 
first breast cancer event (local, regional, or distant recurrence, or 
a new invasive contralateral breast cancer; henceforth referred to 
8010 patients enrolled in BIG 1-98
5786 with FFPE
block assessed
305 unsuccessful for DNA isolation
1294 Letrozole1243 Tamoxifen
2224 blocks not available 
5166 with block
 punched for cores
4861 DNA isolated 
for genotyping
4393 included in analysis
• 564 inadequate material 
• 7 inadequate consent
• 49 arrived late
• 179 failed all CYP2D6 genotyping
• 235 inadequate CYP2D6 genotyping 
 for phenotype classificiation
• 54 ER absent by central review
 
2537 monotherapy
included in analysis of
BCFI
1856 sequential therapy
906 Letrozole
Tamoxifen
950 Tamoxifen
Letrozole
4393 included in analysis of 
hot flushes during first 2 years
2200 Letrozole2193 Tamoxifen
Figure 1. Flow diagram of the Breast International Group (BIG) 1-98 trial 
participants included in the study. Collection of tumor tissue blocks, 
DNA extraction, CYP2D6 genotyping, and patient cohorts for analysis 
are shown. BCFI = breast cancer-free interval; CYP2D6 = Cytochrome 
P450 2D6; ER = estrogen receptor; FFPE = formalin-fixed paraffin- 
embedded.
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as recurrence) ignoring second (non-breast) cancers (24). In the 
absence of an event, BCFI was censored at the last follow-up visit, 
death without a previous cancer event (3.5% of patients), or at 
selective crossover from tamoxifen to letrozole after dissemina-
tion of the primary trial results in 2005 (2). Although the updated 
trial analysis at a median follow-up of 76 months implemented an 
inverse probability of censoring weighted analysis (25), which 
estimated the relative benefit of letrozole vs tamoxifen mono-
therapy that would have been observed in the absence of selective 
crossover of 25% of patients assigned tamoxifen, it was reason-
ably approximated by an unweighted analysis with censoring at 
the time of selective crossover to letrozole (4,5). For this investi-
gation of tamoxifen metabolism, the primary analysis used the 
unweighted censored analysis approach. BCFI was estimated 
using the Kaplan–Meier method. Cox proportional hazards mod-
eling, stratified by two- or four-arm randomization option, was 
used to estimate hazard ratios (HRs) with 95% confidence inter-
vals (CIs). The model included the three-way interaction of treat-
ment, previous neoadjuvant or adjuvant chemotherapy use, and 
CYP2D6 phenotype. The model also adjusted for characteristics 
at random assignment (race [white vs all other], local therapy 
[mastectomy vs breast-conserving surgery], tumor size [≤2 vs >2 cm], 
tumor grade [1, 2, 3], nodal status [positive vs negative], peritu-
moral vascular invasion [absent, present, not assessed], HER2 
status [positive vs negative], Ki-67 labeling index [<14% vs ≥14% 
immunostained cells]). The primary hypothesis tested the associ-
ation of CYP2D6 metabolism phenotype (2 df Wald test) with 
BCFI in tamoxifen-treated patients without previous chemo-
therapy, with secondary tests in the other three subgroups 
defined by randomized endocrine treatment and previous chemo-
therapy use. There was no adjustment for multiple hypothesis 
testing. The proportional hazards assumption was assessed by 
testing for genotype-by-time interaction overall and within each 
of the four subgroups.
Time to onset of hot flushes or night sweats (henceforth 
referred to as hot flushes) within the first 2 years of treatment 
was defined from random assignment to the first report of new 
or worsening events of any grade within 23 months of random 
assignment because most treatment-induced hot flushes began 
during that period (5). Patients were analyzed according to 
the assigned treatment for the first 2 years of the 5-year treat-
ment, which may have been monotherapy or sequential therapy 
(Figure 1). Cumulative incidence was estimated as one minus the 
Kaplan–Meier estimate. A Cox model for hot flush onset was 
adjusted for characteristics at random assignment (race [white vs all 
other], age [<60, 60–64, 65–69, ≥70 years], body mass index [<18.5, 
18.5–29.9, >30 kg/m2], history of hormone replacement therapy 
use [never, within last 3 months, ≥3 months ago], and hot flushes 
[presence vs absence]).
Among the 1250 patients assigned to tamoxifen monotherapy, 
with 14% events and 37.5% prevalence of reduced CYP2D6 
metabolism phenotype (PM or IM), there was 80% power (two-sided 
a = 0.05) to detect a hazard ratio of 1.55 comparing PM or IM vs 
EM phenotypes.
Results are presented in accordance with REMARK criteria 
(26). All statistical tests were two-sided, and P values less than .05 
were considered statistically significant.
Results
A total of 4861 postmenopausal women with hormone receptor–
positive breast cancer were genotyped for CYP2D6. Most (98%) 
patients were white, 43% had lymph node–positive disease, and 
77% had no previous chemotherapy. Characteristics of the 
patients and their disease according to availability of DNA for 
genotyping were comparable (Table 1). Tumor DNA samples 
from 4861 patients were used for genotyping, and CYP2D6 
metabolism phenotype could be estimated for 4393 patients, which 
were included in the analysis (Figure 1). The classification of 
CYP2D6 metabolism based on previously reported genotype 
combinations (23) showed 8.3% PM, 29.5% IM, and 62.2% EM 
phenotypes (Table 2). Fewer than 20% of trial patients discontinued 
their assigned treatment before 5 years for discretionary reasons 
(ie, other than breast cancer recurrence, second non-breast cancer, 
or selective crossover). Discontinuation was not associated with 
CYP2D6 phenotype (P = .97; data not shown).
Association Between CYP2D6 Phenotypes and Breast 
Cancer–Free Interval
A total of 2537 of 4393 patients were assigned to tamoxifen (n = 
1243 patients) or letrozole (n = 1294 patients) monotherapy, in 
whom we investigated the association of CYP2D6 metabolism 
phenotype with BCFI (Figure 1). Because previous studies (7,9,10) 
mostly focused on patients who had received tamoxifen without 
previous chemotherapy, our investigations separated patients 
according to previous chemotherapy use.
Among tamoxifen-treated patients without previous chemo-
therapy, no association between CYP2D6 metabolism phenotype 
and BCFI was noted (P = .35) (Figure 2, A). The PM and IM 
phenotypes, individually as well as combined, had a non-statistically 
significantly reduced risk of breast cancer event compared with 
the EM phenotype (PM vs EM, HR of recurrence = 0.58, 95% 
CI = 0.28 to 1.21; IM vs EM, HR of recurrence = 0.95, 95% 
CI = 0.50 to 1.40; PM and IM combined vs EM, HR of 
recurrence = 0.86, 95% CI = 0.60 to 1.24) (Figure 2, A and 
Supplementary Table 2, available online). No association was also 
noted among tamoxifen-treated patients with previous chemo-
therapy (P = .23) (Figure 2, B).
Among letrozole-treated patients without previous chemo-
therapy, no association between CYP2D6 metabolism phenotype 
and BCFI was noted (P = .98) (Figure 2, C). No association was 
also noted among letrozole-treated patients with previous chemo-
therapy (P = .34) (Figure 2, D). Univariate (unadjusted) and multi-
variable (adjusted) analyses of associations between CYP2D6 
metabolism phenotype with BCFI for both tamoxifen- and 
letrozole-treated groups are summarized in Supplementary Table 2 
(available online).
Some previous clinical investigations (7,9,10) classified patients’ 
CYP2D6 metabolism phenotype based solely on the most preva-
lent PM allele in white populations, CYP2D6*4. The associations 
with BCFI in tamoxifen-treated patients without previous chemo-
therapy based upon CYP2D6*4 were consistent with those based 
on the CYP2D6 metabolism phenotype (P = .34) (Figure 3, A). 
Patients who were homozygous (CYP2D6*4/*4, analogous to the 
PM phenotype) or heterozygous (CYP2D6*4/WT, analogous to 
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the IM phenotype) for CYP2D6*4 variant allele had risks of breast 
cancer events that were not statistically significantly different from 
patients who were homozygous for wild-type alleles (WT/WT, 
analogous to the EM phenotype) (CYP2D6*4/*4 vs WT/WT, HR 
of recurrence = 0.57, 95% CI = 0.26 to 1.23; CYP2D6*4/WT vs 
WT/WT, HR of recurrence = 1.01, 95% CI = 0.66 to 1.56). Another 
point of inconsistency in the literature is whether patients who 
carry only one reduced or null function allele, that is, heterozygous 
carriers of one IM or PM allele (hetEM alleles), were classified 
as having IM or EM phenotype (9,10). In tamoxifen-treated 
Table 1. Characteristics of patients in the BIG 1-98 trial according to availability of DNA for genotyping*
Characteristic
DNA for CYP2D6 genotyping†
No (n = 3149 patients) Yes (n = 4861 patients)
Two-arm or four-arm randomization, % 66 84
Median follow-up, mo 73 72
Postmenopausal, % 100 100
White race, % 97 98
Age, median (IQR), y 61 (55–67) 61 (56–67)
BMI, median (IQR), kg/m2 26 (22–29) 26 (22–29)
Mastectomy, % 46 42
Previous (neo)adjuvant chemotherapy, % 29 23
Lymph node positive, % 38 43
Tumor size > 2 cm, % 34 39
Tumor grade 2 or 3, % 60 67
Peritumoral vascular invasion present 18 17
Centrally assessed tumor features‡  
 ER absent, % 2 1
 HER2 positive, % 7 6
 Ki-67 LI of immunostained cells, median (IQR), % 10 (5–16) 12 (7–19)
* Eligible for enrollment in the randomized, phase III double-blind Breast International Group (BIG) 1-98 trial were postmenopausal women with hormone  
receptor–positive operable invasive breast cancer. BMI = body mass index; CYP2D6 = Cytochrome P450 2D6; ER = estrogen receptor; IQR = interquartile range; 
LI = labeling index.
† Genomic DNA was isolated from formalin-fixed paraffin-embedded primary breast cancer tissue blocks from 4861 BIG 1-98 trial patients. Genotyping for nine 
CYP2D6 single-nucleotide polymorphisms was done using polymerase chain reaction–based methods.
‡ Centrally assessed tumor features were available for a subset of the trial patients (1515 of 3149 patients with no DNA for genotyping; 4776 of 4861 patients with 
DNA available for genotyping).
Table 2. CYP2D6 genotyping and prevalence of CYP2D6 metabolism phenotype in BIG 1-98 trial participants*
CYP2D6 allele†
 Assessable,  
No.
Polymorphic  
alleles, No. (%)
Genotype, %
SNP Homozygous Heterozygous Wild-type
CYP2D6*4 1846G>A (rs2892097) 3828 1444 (18.9) 8.6 20.5 70.9
CYP2D6*2, *4, *10, *41 4180G>C (rs1135840) 0 — — — —
CYP2D6*10,*4 100C>T (rs1065852) 0 — — — —
CYP2D6*41 2988G>A (rs28371725) 3842 643 (8.4) 4.2 8.4 87.4
CYP2D6*3 2549delA (rs35742686) 3012 80 (1.3) 0.4 1.9 97.7
CYP2D6*6 1707delT (rs5030655) 2707 101 (1.9) 0.2 3.3 96.5
CYP2D6*7 2935A>C (rs5030867) 2767 0 0.0 0.0 100.0
CYP2D6*17 1023C>T (rs28371706) 0 — — — —
2850C>T (rs16947) 2285 1550 (33.9) 16.2 35.4 48.4
CYP2D6 metabolism  
 phenotype‡, No. (%)
     
Patients classified — 4393 (100.0) — — — —
 Poor metabolizer — 365 (8.3) — — — —
 Intermediate metabolizer — 1294 (29.5) — — — —
 Extensive metabolizer — 2734 (62.2) — — — —
* BIG = Breast International Group; CYP2D6 = Cytochrome P450 2D6; SNP = single-nucleotide polymorphism; — = not applicable.
† CYP2D6*4 (1846G>A; rs2892097) and CYP2D6*41 (2988G>A; rs28371725) were genotyped in all 4861 patient DNA samples; other alleles were genotyped 
in 3691 patient DNA samples. One hundred seventy-nine patient DNA samples failed CYP2D6 genotyping. Genotyping was done using polymerase chain 
reaction–based methods.
‡ Patients were categorized into predicted metabolism phenotypes as follows: poor metabolizer (PM) phenotypes were homozygous or compound heterozygous 
for CYP2D6*3, CYP2D6*4, CYP2D6*6 or CYP2D6*7 alleles (PM alleles); intermediate metabolizer (IM) phenotypes carried either homozygous CYP2D6*41 alleles 
(IM alleles) or a CYP2D6*41 allele in combination with a PM allele (ie, IM/IM or IM/PM alleles, respectively; n = 215 patients; 5%), or were heterozygous 
carriers of one PM or IM allele with an extensive metabolizer (EM) allele (heterozygous for EM allele or hetEM; n = 1079 patients; 24.5%); EM phenotypes  
were characterized by the absence of PM and IM alleles.
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patients without previous chemotherapy who had IM phenotype, 
the subgroup of patients with hetEM alleles had similar out-
come as the subgroup of patients with IM/IM or IM/PM alleles 
(Figure 3, B).
Association Between CYP2D6 Phenotypes and  
Treatment-Induced Hot Flushes
Among all 4393 patients assigned tamoxifen or letrozole mono-
therapy (n = 2537 patients) or sequential therapy (n = 1856 
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Figure 2. Kaplan–Meier estimates of breast cancer-free interval (BCFI) 
according to CYP2D6 metabolism phenotype, endocrine treatment, and 
previous chemotherapy use in the Breast International Group (BIG) 1-98 
trial. Outcome of 1243 patients randomly assigned to 5 years of tamox-
ifen monotherapy or 1294 patients randomly assigned to 5 years of 
letrozole monotherapy in the BIG 1-98 trial is shown. Based on CYP2D6 
genotyping, metabolism phenotypes were classified as poor metabolizer 
(PM), intermediate metabolizer (IM), and extensive metabolizer (EM). A) 
Tamoxifen without previous chemotherapy. B) Tamoxifen after chemo-
therapy. C) Letrozole without previous chemotherapy. D) Letrozole after 
chemotherapy. P values were calculated using two-sided Wald tests 
with 2 df for association of CYP2D6 metabolism phenotype with BCFI 
within an adjusted Cox proportional hazards model. CI = confidence 
interval; CYP2D6 = Cytochrome P450 2D6; HR = hazard ratio.
jnci.oxfordjournals.org   JNCI | Articles 447
patients), we investigated new onset or worsening hot flushes 
during the first 2 years of therapy (Figure 1). Among the 1706 
patients without previous chemotherapy who initiated treatment 
with tamoxifen, there was an association of CYP2D6 metabolism 
phenotype with hot flushes (P = .020) (Figure 4, A). The PM and 
IM phenotypes had a statistically significantly increased risk of 
tamoxifen-induced hot flushes compared with the EM phenotype 
(PM vs EM, HR of hot flushes = 1.24, 95% CI = 0.96 to 1.59; and 
IM vs EM, HR of hot flushes = 1.23, 95% CI = 1.05 to 1.43) 
(Supplementary Table 3, available online). The cumulative inci-
dence of hot flushes within 2 years of starting tamoxifen was 48% 
(95% CI = 39% to 56%) in patients with PM phenotype and 49% 
(95% CI = 44% to 53%) in patients with IM phenotype as 
compared with 42% (95% CI = 39% to 45%) in patients with 
EM phenotype (Figure 4, A). Among tamoxifen-treated patients 
with previous chemotherapy, no association between CYP2D6 
phenotype and hot flushes was noted (P = .81) (Figure 4, B).
Patients in the letrozole-treated group without previous che-
motherapy showed no association between CYP2D6 phenotype 
and hot flushes (P = .72) (Figure 4, C), and no association was also 
noted among patients with previous chemotherapy (P = .06) 
(Figure 4, D). Univariate (unadjusted) and multivariable (adjusted) 
analyses of associations between CYP2D6 metabolism phenotype 
and hot flushes for both tamoxifen- and letrozole-treated groups 
are summarized in Supplementary Table 3 (available online).
Discussion
In contrast to our hypothesis, we found no association of CYP2D6 
metabolism phenotype with BCFI among postmenopausal patients 
treated with tamoxifen, with or without previous chemotherapy, in 
the BIG 1-98 trial. The patients who received 5 years of tamoxifen 
and were classified as having a PM or IM phenotype did not 
have poorer disease control than those classified as having EM 
phenotype. Based on our results, CYP2D6 pharmacogenetic 
testing is not justified to determine whether adjuvant tamoxifen 
should be given to postmenopausal women with endocrine-
responsive breast cancer.
We did not observe a treatment-by-phenotype interaction in 
the study, and thus the magnitude of benefit of letrozole over 
tamoxifen was the same among EMs as in the study as a whole. 
This result refutes the modeling supposition of Punglia et al. (8) 
that EMs might receive similar or perhaps greater benefit from 
adjuvant tamoxifen than an aromatase inhibitor.
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Figure 3. Kaplan–Meier estimates of breast cancer-free interval (BCFI) 
among tamoxifen-treated patients in the Breast International Group 
(BIG) 1-98 trial according to CYP2D6 metabolism phenotype. Outcome 
of 973 patients without previous chemotherapy who were randomly 
assigned to 5 years of tamoxifen monotherapy. P values were calcu-
lated using two-sided Wald tests with 2 df for association of CYP2D6 
(continued)
metabolism phenotype with BCFI within adjusted Cox proportional 
hazards models. A) Phenotype classification based only on CYP2D6*4 
allele. Homozygous CYP2D6*4/*4 (shown as *4/*4) is analogous to the 
poor metabolizer (PM) phenotype; heterozygous CYP2D6*4/WT (shown 
as *4/WT) is analogous to the intermediate metabolizer (IM) phenotype; 
homozygous for wild-type alleles (WT/WT) is analogous to the exten-
sive metabolizer (EM) phenotype. B) Phenotype classification with 
separation of two IM phenotype subgroups, defined as carriers of either 
homozygous CYP2D6*41 alleles or a CYP2D6*41 allele in combination 
with a PM allele (ie, IM/IM or IM/PM alleles, respectively), or defined as 
heterozygous carriers of one PM or IM allele and one EM allele (ie, 
heterozygous for EM alleles [hetEM]). CI = confidence interval; CYP2D6 
= Cytochrome P450 2D6; HR = hazard ratio.
Figure 3. (continued).
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We found that the PM and IM phenotypes of CYP2D6 were 
not associated with reduced hot flushes, rather, we observed a 
greater incidence of tamoxifen-induced hot flushes in these 
patients. This finding is in contrast to the hypothesis that lower 
endoxifen levels are manifest by fewer or less severe tamoxifen-
induced hot flushes, which was based on an observation that 
none of 13 patients with CYP2D6*4/*4 genotype (PM phenotype) 
had moderate or severe hot flushes (7). Two subsequent studies 
reported mixed results (20,21), with one study reporting the 
highest incidence of hot flushes in the IM group (21), consistent 
with our observations. If, as others have reported, there is an asso-
ciation of hot flushes to breast cancer outcome (27,28), then it is 
because of some other mechanism. Based on our results and others 
(21), the presence or absence of hot flushes should not be used to 
estimate tamoxifen metabolism when making treatment decisions.
Our results indicate that CYP2D6 metabolism phenotype is not 
the correct surrogate for predicting symptoms and outcome of 
tamoxifen-treated postmenopausal women, and conclude that the 
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Figure 4. Cumulative incidence of new or worsening hot flushes during 
the first 2 years of treatment in the Breast International Group (BIG) 
1-98 trial according to CYP2D6 metabolism phenotype. Results of all 
4393 patients whose phenotypes were poor metabolizer (PM), interme-
diate metabolizer (IM), and extensive metabolizer (EM). All P values 
were calculated using two-sided Wald tests with 2 df for association of 
CYP2D6 metabolism phenotype with onset of hot flushes within 
an adjusted Cox proportional hazards model. A) Tamoxifen without 
previous chemotherapy. B) Tamoxifen after previous chemotherapy. C) 
Letrozole without previous chemotherapy. D) Letrozole after pre-
vious chemotherapy. CI = confidence interval; CYP2D6 = Cytochrome 
P450 2D6.
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relationship of tamoxifen metabolism with symptoms and disease 
control is not adequately understood. The hypothesis underlying 
our investigation—that CYP2D6 polymorphisms leading to 
reduced enzyme activity result in lower endoxifen levels, which 
adversely affects tamoxifen efficacy—was not tested in our clinical 
study, as we did not measure endoxifen levels. We can only 
conclude that CYP2D6 metabolism phenotype does not predict 
tamoxifen efficacy.
The role of endoxifen in tamoxifen efficacy is controversial. 
Endoxifen has greater affinity for ER than tamoxifen (13,14), and 
endoxifen may be the most important tamoxifen metabolite, with 
higher plasma concentrations than 4-hydroxytamoxifen 
(15,16,18,19) and similar ER affinity (13,14). Furthermore, endox-
ifen appears to have a different mechanism of action from 
4-hydroxytamoxifen by targeting ERa for degradation, as opposed 
to stabilizing ERa, and inhibiting estradiol-mediated upregulation 
of amphiregulin, a ligand of epidermal growth factor receptor (17). 
The interest in endoxifen is such that endoxifen citrate (29) and 
Z-Endoxifen hydrochloride (18) are being developed as therapeutics 
(clintrials.gov NCT01273168). However, plasma concentrations of 
tamoxifen and a primary metabolite N-desmethyltamoxifen are 
higher than both endoxifen and 4-hydroxytamoxifen (15,16,18,19), 
and tamoxifen and metabolites N-desmethyltamoxifen, dides-
methyltamoxifen, and 4-hydroxytamoxifen have been estimated to 
nearly saturate ER with 99.94% occupancy (30). In addition, ERa 
degradation has not been evidenced in neoadjuvant tamoxifen 
trials (31). Thus, further elucidation of tamoxifen metabolism and 
efficacy are needed.
The Women’s Healthy Eating and Living (WHEL) study of 
breast cancer survivors recently reported on the relationship 
between endoxifen levels and outcome in a cohort of 1370 women 
with ER-positive early breast cancer, who were enrolled in the 
WHEL study if recurrence free and within 4 years of diagnosis, 
and who had been taking tamoxifen for at least 4 months before 
blood collection (32). There was no evidence of an increasing 
hazard of disease recurrence with decreasing endoxifen levels 
(considered in quintiles), but an increased hazard in the lowest 
quintile (ie, among the 20% of patients with the lowest endoxifen 
levels) was observed, and the authors postulated a minimum critical 
concentration threshold for endoxifen, which was associated with 
an IM or PM phenotype, high body mass index, and lower tamoxifen 
concentrations. They concluded that metabolism phenotype alone 
may not be sufficient to predict an individual’s tamoxifen efficacy, 
as about one-quarter of patients with PM phenotype had endoxifen 
levels above the threshold.
Prospective clinical trials are needed to better understand the 
relationship between CYP2D6 metabolism phenotype, active 
metabolite concentrations, and outcomes. An ongoing prospective 
trial in the United States is Eastern Cooperative Oncology Group 
(ECOG) Trial 3108 (clinicaltrials.gov NCT01124695). This phase 
II trial of 240 patients with metastatic breast cancer treated with 
single-agent tamoxifen will assess the relationship of CYP2D6 
activity with progression-free survival and response, and of 
endoxifen concentration with response.
Differences in published clinical studies include alleles 
genotyped, lack of a standardized definition of CYP2D6 metabo-
lism phenotype, and regional and time-linked variation in the 
concomitant use of CYP2D6 inhibitors with tamoxifen (9). These 
factors have been further complicated by varied study designs, 
patient populations and endpoint definitions, and use of mostly 
retrospective investigations in small clinical trials or convenience 
samples. The results have been correspondingly conflicting. Our 
study, together with a recent study in the Arimidex, Tamoxifen, 
Alone or in Combination (ATAC) trial (33), overcome most of the 
shortcomings and draw similar conclusions.
This study has a few limitations. Despite being the largest inves-
tigation to date, with almost 5000 patients genotyped who were 
consistently treated and followed in a clinical trial, it does not 
address all clinical issues in relation to CYP2D6 genotype. One such 
issue is whether patients should avoid the concomitant administra-
tion of tamoxifen and CYP2D6 inhibitors, such as selective sero-
tonin reuptake inhibitors. Information on concomitant medications 
was not collected in BIG 1-98 trial. It is commonly suggested that 
patients receiving tamoxifen should avoid potent inhibitors when 
possible (9–11), based not only on studies showing variation in 
plasma endoxifen levels according to a CYP2D6 metabolism pheno-
type definition that includes CYP2D6 inhibitor drugs but also on the 
purported association of phenotype with outcome. This suggestion 
is controversial (33,34), and our study cannot contribute to the clin-
ical decision about whether to avoid CYP2D6 inhibitors with tamox-
ifen treatment. By genotyping only a small set of CYP2D6 SNPs, 
there may be some misclassification of metabolism phenotype. 
Others have reported increased hazard ratios of nearly 2.0 for PM 
and IM vs EM phenotypes (7,9,10). In order for our study to have 
obscured a true hazard ratio of 1.5 and observed a hazard ratio near 
1.0, 75% of patients classified as EMs would have to have been 
misclassified. Another consideration in all clinical investigations of 
CYP2D6 is whether patients completed 5 years of tamoxifen. One 
study specifically studied the issue and observed higher discontinua-
tion of tamoxifen at 4 months among patients with greater CYP2D6 
activity scores (35). In BIG 1-98 trial, discontinuation of assigned 
treatment was not associated with CYP2D6 metabolism phenotype.
In conclusion, in the BIG 1-98 trial of postmenopausal women 
who received 5 years of adjuvant tamoxifen with or without 
previous chemotherapy, CYP2D6 phenotypes of reduced enzyme 
activity were not associated with worse disease control. CYP2D6 
PM and IM phenotypes were not associated with reduced tamoxifen-
induced hot flushes. Results suggest that CYP2D6 pharmacoge-
netic testing is not justified to determine whether tamoxifen should 
be given to postmenopausal women nor to withhold treatment 
with an aromatase inhibitor. The presence or absence of hot 
flushes should not be used in the clinical setting to estimate tamox-
ifen efficacy. Our conclusions are only in postmenopausal women. 
The role of CYP2D6 in premenopausal women is unknown; for 
premenopausal patients, investigation of pharmacogenetic testing 
is ongoing in the Tamoxifen and Exemestane Trial (TEXT; 
identifier NCT00066703 at clinicaltrials.gov) and Suppression of 
Ovarian Function Trial (SOFT; identifier NCT00066690 at 
clinicaltrials.gov).
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